Comparative Pharmacology
Head-to-head clinical analysis: IQUIX versus MOXEZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IQUIX versus MOXEZA.
IQUIX vs MOXEZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
400 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Terminal half-life: 12 hours; allows once-daily dosing
Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic